Validation of molecular targets in prostate cancer

BJU International, Supplement

Volumn 96, Issue 2, 2005, Pages 23-29

  Schalken, Jack A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Androgen receptor; Cadherin; Hormone refractory prostate cancer; Prostate cancer stem cell; Prostate cancer specific genes

Indexed keywords

ANDROGEN RECEPTOR; CADHERIN;

CANCER STEM CELL; CONFERENCE PAPER; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; ONCOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VALIDATION PROCESS;

ANDROGENS; ANTIGENS, NEOPLASM; CADHERINS; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TUMOR STEM CELLS;

EID: 29944438497     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05943.x     Document Type: Conference Paper

References (54)

1. Clarke RB, Spence K, Anderson E, Howell A, Okano H, Potten CS. A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev Biol 2005; 277: 443-56
2. Schalken J. Molecular diagnostics and therapy of prostate cancer: new avenues. Eur Urol 1998; 34 (Suppl. 3): 3-6
3. Watson RW, Schalken JA. Future opportunities for the diagnosis and treatment of prostate cancer. Prostate Cancer Prostatic Dis 2004; 7 (Suppl. 1): S8-13
4. Yu J, Shannon WD, Watson MA, McLeod HL. Gene expression profiling of the irinotecan pathway in colorectal cancer. Clin Cancer Res 2005; 11: 2053-62
5. Denmeade SR, Isaacs JT. Development of prostate cancer treatment: the good news. Prostate 2004; 58: 211-24
6. van der Poel HG. Smart drugs in prostate cancer. Eur Urol 2004; 45: 1-17
7. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003; 3: 110-6
8. Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 2003; 22: 6524-36
9. Hessels D, Verhaegh GW, Schalken JA, Witjes JA. Applicability of biomarkers in the early diagnosis of prostate cancer. Expert Rev Mol Diagn 2004; 4: 513-26
10. Verhaegh GW, van Bokhoven A, Smit F, Schalken JA, Bussemakers MJ. Isolation and characterization of the promoter of the human prostate cancer-specific DD3 gene. J Biol Chem 2000; 275: 37496-503
11. Bussemakers MJ, van Bokhoven A, Verhaegh GW et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59: 5975-9
12. Srikantan V, Zou Z, Petrovics G et al. PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc Natl Acad Sci USA 2000; 97: 12216-21
13. Petrovics G, Zhang W, Makarem M et al. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogens 2004; 23: 605-11
14. Wright GL Jr, Grob BM, Haley C et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48: 326-34
15. Watabe T, Lin M, Ide H et al. Growth, regeneration, and tumorigenesis of the prostate activates the PSCA promoter. Proc Natl Acad Sci USA 2002; 99: 401-6
16. Zhigang Z, Wenlv S. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues, implications for prostate carcinogenesis and progression of prostate cancer. Jpn J Clin Oncol 2004; 34: 414-9
17. de Kok JB, Verhaegh GW, Roelofs RW et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002; 62: 2695-8
18. Hessels D, Klein Gunnewiek JMT, van Oort I et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44: 8-16
19. van der Poel HG, McCadden J, Verhaegh GW et al. A novel method for the determination of basal gene expression of tissue-specific promoters: an analysis of prostate-specific promoters. Cancer Gene Ther 2001; 8: 927-35
20. Fradet Y, Saad F, Aprikian A et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004; 64: 311-6
21. Tinzl M, Marberger M, Horvath S, Chypre C. DD3PCA3 RNA analysis in urine-a new perspective for detecting prostate cancer. Eur Urol 2004: 46: 182-7
22. Litvinov IV, De Marzo AM, Isaacs JT. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 2003; 88: 2972-82
23. van Leenders GJ, Schalken JA. Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis. BJU Int 2001: 88 (Suppl. 2): 35-42
24. Luo J, Lubaroff DM, Hendrix MJ. Suppression of prostate cancer invasive potential and matrix metalloproteinase activity by E-cadherin transfection. Cancer Res 1999: 59: 3552-6
25. Umbas R, Isaacs WB, Bringuier PP, Xue Y, Debruyne FM, Schalken JA. Relation between aberrant α-catenin expression and loss of E-cadherin function in prostate cancer. Int J Cancer 1997; 74: 374-7
26. Biroccio A, Leonetti C. Telomerase as a new target for the treatment of hormone-refractory cancer. Endocr Relat Cancer 2004; 11: 407-21
27. Grignon DJ. Unusual subtypes of prostate cancer. Mod Pathol 2004; 17: 316-27
28. Lapointe J, Li C, Higgins JP et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc NAtl Acad Sci U S A 2004; 101: 811-6
29. Gonzalgo ML, Isaacs WB. Molecular pathways to prostate cancer. J Urol 2003; 170: 2444-52
30. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004; 113: 913-23
31. Eder IE, Culig Z, Putz T et al. Molecular biology of the androgen receptor: from molecular understanding to the clinic. Eur Urol 2001; 40: 241-51
32. Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer 2002; 2: 389-96
33. Hamdy FC, Thomas BG. New therapeutic concepts in prostate cancer. BJU Int 2001; 88 (Suppl. 2): 43-8
34. van der Kwast TH, Schalken J, Ruizeveld de Winter JA et al. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 1991; 48: 189-93
35. Culig Z. Role of the androgen receptor axis in prostate cancer. Urology 2003; 62 (5 Suppl. 1): 21-6
36. Taplin ME, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 2004; 91: 483-90
37. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003; 3: 895-902
38. Schalken JA, van Leenders G. Cellular and molecular biology of the prostate: stem cell biology. Urology 2003; 62: 11-20
39. van Leenders G, Dijkman H, Hulsbergen-van de Kaa C, Ruiter D, Schalken J. Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy. Lab Invest 2000; 80: 1251-8
40. Xue Y, Smedts F, Verhofstad A, Debruyne F, de la Rosette J, Schalken J. Cell kinetics of prostate exocrine and neuroendocrine epithelium and their differential interrelationship: new perspectives. Prostate Suppl 1998; 8: 62-73
41. Al Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogens 2004; 23: 7274-82
42. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 1989; 2: 33-50
43. Lang SH, Stark M, Collins A, Paul AB, Stower MJ, Maitland NJ. Experimental prostate epithelial morphogenesis in response to stroma and three-dimensional matrigel culture. Cell Growth Differ 2001: 12: 631-40
44. 1-integrin expression. J Cell Sci 2001; 114: 3865-72
45. van Leenders G, van Balken B, Aalders T, Hulsbergen-van de Kaa C, Ruiter D, Schalken J. Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion. Prostate 2002; 51: 98-107
46. van Leenders GJLH, Schalken JA. Epithelial cell differentiation in the human prostate epithelium: implications for the pathogenesis and therapy of prostate cancer. Crit Rev Oncol Hematol 2003; 46 (Suppl.): S3-10
47. van Leenders GJ, Aalders TW, Hulsbergen-van de Kaa CA, Ruiter DJ, Schalken JA. Expression of basal cell keratins in human prostate cancer metastases and cell lines. J Pathol 2001; 195: 563-70
48. Long RM, Morrissey C, Fitzpatrick JM, Watson RW. Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies. Clin Sci (Lond) 2005; 108: 1-11
49. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1994; 1198: 11-26
50. Umbas R, Schalken JA, Aalders TW et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992; 52: 5104-9
51. Pedersen KB, Nesland JM, Fodstad Ø, Mælandsmo GM. Expression of S100A4, E-cadherin, α- and β-catenin in breast cancer biopsies. Br J Cancer 2002; 87: 1281-6
52. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001; 411: 349-54
53. Rizvi AZ, Wong MH. Epithelial stem cells and their niche: there's no place like home. Stem Cells 2005; 23: 150-65
54. Foster CS, Dodson A, Karavana V, Smith PH, Ke Y. Prostatic stem cells. J Pathol 2002; 197: 551-65